Hsp90: an emerging target for breast cancer therapy
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Pharmacology (medical),Pharmacology,Oncology
Reference156 articles.
1. Breast health and disease over a lifetime;Osuch;Clin Obstet Gynecol,2002
2. Cancer Facts and Figures 2003,2003
3. Selective estrogen receptor modulators: structure, function, and clinical use;Osborne;J Clin Oncol,2000
4. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling;Clarke;Oncogene,2003
5. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance;Schiff;Clin Cancer Res,2004
Cited by 131 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Synthesis of new antiproliferative 1,3,4-substituted-pyrrolo[3,2-c]quinoline derivatives, biological and in silico insights;European Journal of Medicinal Chemistry;2023-10
2. Design, Docking, In silico ADME Prediction of Novel 2-substituted-5- hydroxy-1-(1-methyl-3-morpholinopropyl)-1H-indole-3-carboxamide Derivatives for Estrogen Receptor Alfa in AF-2 Domain for Effective Anticancer Treatment;Letters in Drug Design & Discovery;2023-08
3. Uncovering the molecular mechanism of Gynostemma pentaphyllum (Thunb.) Makino against breast cancer using network pharmacology and molecular docking;Medicine;2022-12-09
4. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer;npj Breast Cancer;2022-12-01
5. Development of machine learning models for the screening of potential HSP90 inhibitors;Frontiers in Molecular Biosciences;2022-10-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3